BMY vs. PFE
BMY (Bristol-Myers Squibb Company) and PFE (Pfizer Inc.) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, BMY returned 0.92%/yr vs 2.09%/yr for PFE. At a 0.47 correlation, their price movements are largely independent.
Performance
BMY vs. PFE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BMY achieves a 8.54% return, which is significantly higher than PFE's 8.09% return. Over the past 10 years, BMY has underperformed PFE with an annualized return of 0.92%, while PFE has yielded a comparatively higher 2.09% annualized return.
BMY
- 1D
- 1.18%
- 1M
- 1.20%
- YTD
- 8.54%
- 6M
- 12.26%
- 1Y
- 25.69%
- 3Y*
- 0.16%
- 5Y*
- 1.52%
- 10Y*
- 0.92%
PFE
- 1D
- 1.36%
- 1M
- -0.23%
- YTD
- 8.09%
- 6M
- 3.39%
- 1Y
- 20.50%
- 3Y*
- -6.48%
- 5Y*
- -2.98%
- 10Y*
- 2.09%
BMY vs. PFE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 8.54% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
PFE Pfizer Inc. | 8.09% | 0.65% | -2.22% | -41.26% | -10.41% | 66.70% | 3.07% | -6.91% | 24.82% | 15.90% |
Correlation
The correlation between BMY and PFE is 0.64, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.64 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.50 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.50 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.48 |
Correlation (All Time) Calculated using the full available price history since Jun 2, 1972 | 0.47 |
The correlation between BMY and PFE shifts across timeframes, from 0.47 (all time) to 0.64 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
BMY:
$117.03B
PFE:
$149.24B
BMY:
$3.57
PFE:
$1.31
BMY:
16.06
PFE:
19.85
BMY:
0.92
PFE:
0.36
BMY:
2.41
PFE:
2.35
BMY:
5.83
PFE:
1.66
BMY:
$48.48B
PFE:
$63.32B
BMY:
$33.33B
PFE:
$43.91B
BMY:
$13.34B
PFE:
$16.94B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BMY vs. PFE — Risk / Return Rank
BMY
PFE
BMY vs. PFE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BMY | PFE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.10 | ||
| Sortino ratioReturn per unit of downside risk | +0.13 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 1.17 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 1.89 | 1.79 | +0.09 |
| Martin ratioReturn relative to average drawdown | 4.15 | 3.68 | +0.47 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BMY | PFE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.96 | 0.86 | +0.10 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.06 | -0.12 | +0.18 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.04 | 0.09 | -0.05 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.33 | +0.01 |
Drawdowns
BMY vs. PFE - Drawdown Comparison
The maximum BMY drawdown since its inception was -72.03%, roughly equal to the maximum PFE drawdown of -69.24%. Use the drawdown chart below to compare losses from any high point for BMY and PFE.
Loading charts...
Drawdown Indicators
| BMY | PFE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.03% | -69.24% | -2.79% |
Max Drawdown (1Y)Largest decline over 1 year | -13.68% | -11.47% | -2.21% |
Max Drawdown (3Y)Largest decline over 3 years | -36.85% | -40.75% | +3.90% |
Max Drawdown (5Y)Largest decline over 5 years | -47.67% | -58.96% | +11.29% |
Max Drawdown (10Y)Largest decline over 10 years | -47.67% | -58.96% | +11.29% |
Current DrawdownCurrent decline from peak | -17.59% | -46.03% | +28.44% |
Average DrawdownAverage peak-to-trough decline | -22.38% | -22.89% | +0.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.21% | 5.59% | +0.62% |
Volatility
BMY vs. PFE - Volatility Comparison
Bristol-Myers Squibb Company (BMY) has a higher volatility of 7.08% compared to Pfizer Inc. (PFE) at 4.50%. This indicates that BMY's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BMY | PFE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.08% | 4.50% | +2.58% |
Volatility (6M)Calculated over the trailing 6-month period | 17.90% | 14.66% | +3.24% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.83% | 23.92% | +2.91% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.02% | 25.50% | -1.48% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.25% | 23.88% | +1.37% |
Dividends
BMY vs. PFE - Dividend Comparison
BMY's dividend yield for the trailing twelve months is around 4.37%, less than PFE's 6.61% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.37% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
PFE Pfizer Inc. | 6.61% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% |
Financials
BMY vs. PFE - Financials Comparison
This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMY vs. PFE - Profitability Comparison
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
PFE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
PFE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
PFE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.
Frequently Asked Questions
BMY and PFE have a correlation of 0.64, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BMY has higher volatility (7.08%) compared to PFE (4.50%). In terms of maximum drawdown, BMY dropped -72.03% vs PFE's -69.24%.
BMY currently has the higher Sharpe Ratio (0.96 vs 0.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BMY and PFE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer